Revelation Biosciences issues CEO one share of Series A Preferred with 50M votes to secure reverse stock split approval

REVELATION BIOSCIENCES, INC.

CEO James Rolke purchased one share of Series A Preferred for $5,000 cash.
Preferred carries 50,000,000 votes, only on proposals to increase authorized common stock and effect reverse stock split.
Preferred votes in proportion to common stock votes on those proposals; no other voting rights.
Non-convertible, no dividends, no liquidation rights; redeemable at $5,000 upon board order or automatically upon reverse split effectiveness.
Transfer restricted without board consent; issuance exempt under Section 4(a)(2).

item 1.01 item 5.03 item 3.02 item 3.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

REVELATION BIOSCIENCES, INC.: Filed certificate of designation creating a new series of Preferred Stock with designated voting rights, redemption provisions, and other preferences, effective upon filing (effective 2022-12-19).

Change: charter amendment
Effective: 2022-12-19

Exact text from the filing

On December 19, 2022, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the share of Preferred Stock.

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-026866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.